Literature DB >> 14608641

Phenotypic abnormalities: terminology and classification.

Johannes H M Merks1, Clara D M van Karnebeek, Hubert N Caron, Raoul C M Hennekam.   

Abstract

Clinical morphology has proved essential for the successful delineation of hundreds of syndromes and as a powerful instrument for detecting (candidate) genes (Gorlin et al. [2001]; Syndromes of the Head and Neck; Oxford: Oxford University Press. 1 p]. The major approach to reach this has been careful clinical evaluations of patients, focused on congenital anomalies. A similar careful physical examination performed in patients, who have been treated for childhood cancer, may allow detection of concurrent patterns of anomalies and provide clues for causative genes. In the past, several studies were performed describing the prevalence of anomalies in patients with cancer. However, in most studies, it was not possible to indicate the biologic relevance of the recorded anomalies, or to judge their relative importance. Are the detected anomalies common variants, and should they thus be regarded as normal, or are they minor anomalies or true abnormalities, indicating a possible developmental cause? Classification of items in the categories of common variants (disturbances of phenogenesis with a prevalence >4%), minor anomalies (disturbances of phenogenesis with a prevalence </=4%), and malformations (disturbances of embryogenesis) should allow weighing the importance of the scored items in the population under study, and should facilitate assessment of developmental disturbances (if any) in a study group. The lack of published consensus in the literature led us to produce a classification list with a twofold goal. First, we wanted to enhance uniformity in the scoring and classification of apparently abnormal physical findings by a nomenclature for errors of morphogenesis detectable on surface examination, and secondly a uniform classification system. This should allow investigators to evaluate systematically the presence of patterns in phenotypic anomalies, in the general population, and in patients with various disorders, suspected to be a developmental anomaly. Also, normal values may be obtained this way. Second, the list will allow a determination of the importance of the collected symptoms in a study population. We tested the feasibility of the application of the classification list in a study population: the list was piloted in a group of patients who have had cancer as a child, to detect patterns of anomalies related to specific types of tumors. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 14608641     DOI: 10.1002/ajmg.a.20249

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  17 in total

Review 1.  Dysmorphology demystified.

Authors:  William Reardon; Dian Donnai
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-05       Impact factor: 5.747

2.  Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones.

Authors:  Stephanie Padberg; Evelin Wacker; Reinhard Meister; Mary Panse; Corinna Weber-Schoendorfer; Marc Oppermann; Christof Schaefer
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

3.  Disruption of cerebellar development: potential complication of extreme prematurity.

Authors:  Agnes Messerschmidt; Peter C Brugger; Eugen Boltshauser; Gerlinde Zoder; Walter Sterniste; Robert Birnbacher; Daniela Prayer
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

4.  Unilateral cerebellar hypoplasia with different clinical features.

Authors:  Gulcin Benbir; Simay Kara; Beyza Citci Yalcinkaya; Geysu Karhkaya; Beyhan Tuysuz; Naci Kocer; Cengiz Yalcinkaya
Journal:  Cerebellum       Date:  2011-03       Impact factor: 3.847

Review 5.  Pediatric cancer risk in association with birth defects: A systematic review.

Authors:  Kimberly J Johnson; Jong Min Lee; Kazi Ahsan; Hannah Padda; Qianxi Feng; Sonia Partap; Susan A Fowler; Todd E Druley
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

6.  Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre.

Authors:  M Hoeltzenbein; E Beck; K Meixner; C Schaefer; R Kreutz
Journal:  Clin Res Cardiol       Date:  2015-07-21       Impact factor: 5.460

7.  Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services.

Authors:  Alice Panchaud; Valentin Rousson; Thierry Vial; Nathalie Bernard; David Baud; Emmanuelle Amar; Marco De Santis; Alessandra Pistelli; Anne Dautriche; Frederique Beau-Salinas; Matteo Cassina; Hannah Dunstan; Anneke Passier; Yusuf Cem Kaplan; Mine Kadioglu Duman; Eva Maňáková; Georgios Eleftheriou; Gil Klinger; Ursula Winterfeld; Laura E Rothuizen; Thierry Buclin; Chantal Csajka; Sonia Hernandez-Diaz
Journal:  Br J Clin Pharmacol       Date:  2018-01-14       Impact factor: 4.335

8.  Array-based comparative genomic hybridization in 190 Korean patients with developmental delay and/or intellectual disability: a single tertiary care university center study.

Authors:  Cha Gon Lee; Sang-Jin Park; Jun-No Yun; Jung Min Ko; Hyon-Ju Kim; Shin-Young Yim; Young Bae Sohn
Journal:  Yonsei Med J       Date:  2013-11       Impact factor: 2.759

9.  Sexual dimorphism in the prenatal digit ratio (2D:4D).

Authors:  Frietson Galis; Clara M A Ten Broek; Stefan Van Dongen; Liliane C D Wijnaendts
Journal:  Arch Sex Behav       Date:  2009-03-20

10.  Association of Chemotherapy Timing in Pregnancy With Congenital Malformation.

Authors:  Mathilde van Gerwen; Charlotte Maggen; Elyce Cardonick; Emma J Verwaaijen; Marry van den Heuvel-Eibrink; Roman G Shmakov; Ingrid Boere; Mina M Gziri; Petronella B Ottevanger; Christianne A R Lok; Michael Halaska; Long Ting Shao; Ilana Struys; Elisabeth M van Dijk-Lokkart; Kristel Van Calsteren; Robert Fruscio; Paolo Zola; Giovanna Scarfone; Frédéric Amant
Journal:  JAMA Netw Open       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.